2018
DOI: 10.1002/ijgo.12455
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review and meta‐analysis of venous thrombosis risk among users of combined oral contraception

Abstract: BackgroundCombined oral contraceptives (COCs) containing various progestogens could be associated with differential risks for venous thromboembolism (VTE).ObjectiveTo evaluate the comparative risks of VTE associated with the use of low‐dose (less than 50 μg ethinyl estradiol) COCs containing different progestogens.Search strategyPubMed and the Cochrane Library were searched from database inception through September 15, 2016, by combining search terms for oral contraception and venous thrombosis.Selection crite… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
100
1
20

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 166 publications
(123 citation statements)
references
References 52 publications
2
100
1
20
Order By: Relevance
“…The VTE risk is dependent on the estrogen dose, with higher doses associated with increased risk . The progestin agents desogestrel, drospirenone, and cyproterone acetate further increase the risk compared to levonorgestrel for a given estrogen dose . Many patient‐specific factors such as obesity, smoking, and inherited thrombophilias can result in a synergistic increase in VTE risk for ciswomen using COC …”
Section: Case I: Mtfmentioning
confidence: 99%
See 1 more Smart Citation
“…The VTE risk is dependent on the estrogen dose, with higher doses associated with increased risk . The progestin agents desogestrel, drospirenone, and cyproterone acetate further increase the risk compared to levonorgestrel for a given estrogen dose . Many patient‐specific factors such as obesity, smoking, and inherited thrombophilias can result in a synergistic increase in VTE risk for ciswomen using COC …”
Section: Case I: Mtfmentioning
confidence: 99%
“…9 The progestin agents desogestrel, drospirenone, and cyproterone acetate further increase the risk compared to levonorgestrel for a given estrogen dose. 11 Many patient-specific factors such as obesity, smoking, and inherited thrombophilias can result in a synergistic increase in VTE risk for ciswomen using COC. [12][13][14] Although the relative risk increase of VTE associated with HRT is lower than for COC, it is not negligible.…”
Section: Vte Risks With Mtf Hormonal Therapymentioning
confidence: 99%
“…A systematic review identified no relevant RCTs 230. Meta-analysis230 of the data from observational studies (which may be subject to confounding and prescribing bias) indicated that use of low-dose COC (<50 μg EE) containing cyproterone acetate, desogestrel, gestodene or DRSP was associated with a significant 1.5- to 2-fold risk of VTE compared to use of COC containing LNG.…”
Section: Health Risks Associated With Chc Usementioning
confidence: 99%
“…По данным Всемирной организации здравоохранения, в настоящее время комбинированная гормональная контрацепция является эффективным и широко применяемым методом во всем мире, около 104 миллионов женщин ежегодно используют ее с противозачаточной и лечебной целью [1][2][3][4]. Абсолютный риск развития тромбоза среди пациенток, принимающих современные комбинированные гормональные контрацептивы (КГК), низкий, но вместе с тем он в 3-6 раз выше в сравнении с женщинами, не использующими КГК [1][2][3].…”
Section: Fgbou Vo "South Ural State Medical University Ministry Of Heunclassified
“…Абсолютный риск развития тромбоза среди пациенток, принимающих современные комбинированные гормональные контрацептивы (КГК), низкий, но вместе с тем он в 3-6 раз выше в сравнении с женщинами, не использующими КГК [1][2][3]. По данным эпидемиологических исследований, риск венозного тромбоэмболизма (ВТЭ) у женщин, использующих КГК, варьирует в диапазоне 3-9/10000 человеко-лет [4], риск артериальных тромботических осложнений еще ниже и составляет от 0,9 до 3,5/10000 человеко-лет [5]. Установлена обратная зависимость риска тромбозов от дозы эстрогенового компонента, но дискутабельна зависимость от типа прогестина [6].…”
Section: Fgbou Vo "South Ural State Medical University Ministry Of Heunclassified